{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:23:11Z","timestamp":1782876191500,"version":"3.54.5"},"reference-count":62,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although acute lymphoblastic leukemia (ALL) is highly responsive to chemotherapy, it is unknown how or which host immune factors influence the long-term remission of this cancer. To this end, we systematically evaluated the effects of T-cell immunity on Ph+ ALL therapy outcomes. Using a murine Arf\u2212\/\u2212BCR-ABL1 B-cell ALL model, we showed that loss of T cells in the host drastically increased leukemia relapse after dasatinib or cytotoxic chemotherapy. Although ABL1 mutations emerged early during dasatinib treatment in both immunocompetent and immunocompromised hosts, T-cell immunity was essential for suppressing the outgrowth of drug-resistant leukemia. Bulk and single-cell transcriptome profiling of T cells during therapy pointed to the activation of type 1 immunity-related cytokine signaling being linked to long-term leukemia remission in mice. Consistent with these observations, interferon \u03b3 and interleukin 12 directly modulated dasatinib antileukemia efficacy in\u00a0vivo. Finally, we evaluated peripheral blood immune cell composition in 102 children with ALL during chemotherapy and observed a significant association of T-cell abundance with treatment outcomes. Together, these results suggest that T-cell immunity plays pivotal roles in maintaining long-term remission of ALL, highlighting that the interplay between host immunity and drug resistance can be harnessed to improve ALL chemotherapy outcomes.<\/jats:p>","DOI":"10.1182\/blood.2021014495","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T19:02:04Z","timestamp":1654714924000},"page":"1507-1521","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8941-6691","authenticated-orcid":false,"given":"Yizhen","family":"Li","sequence":"first","affiliation":[{"name":"1Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"3Department of Immunology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7305-5649","authenticated-orcid":false,"given":"Wenjian","family":"Yang","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bensheng","family":"Ju","sequence":"additional","affiliation":[{"name":"2Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-6608","authenticated-orcid":false,"given":"John","family":"Easton","sequence":"additional","affiliation":[{"name":"2Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqing","family":"Pei","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[{"name":"4Department of Biostatistics, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Lee","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"5Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[{"name":"6Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"7Hematological Malignancies Program, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1244-4429","authenticated-orcid":false,"given":"Jiyang","family":"Yu","sequence":"additional","affiliation":[{"name":"2Department of Computational Biology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Chi","sequence":"additional","affiliation":[{"name":"3Department of Immunology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0770-9659","authenticated-orcid":false,"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[{"name":"1Division of Pharmaceutical Sciences, Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"6Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"7Hematological Malignancies Program, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022092915292658800_B1","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol."},{"issue":"16","key":"2022092915292658800_B2","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med."},{"issue":"16","key":"2022092915292658800_B3","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood."},{"issue":"8","key":"2022092915292658800_B4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2022092915292658800_B5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/jnci\/djaa138","article-title":"Association of GATA3 polymorphisms with minimal residual disease and relapse risk in childhood acute lymphoblastic leukemia","volume":"113","author":"Zhang","year":"2021","journal-title":"J Natl Cancer Inst."},{"issue":"12","key":"2022092915292658800_B6","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/ng.2803","article-title":"Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse","volume":"45","author":"Perez-Andreu","year":"2013","journal-title":"Nat Genet."},{"issue":"2","key":"2022092915292658800_B7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri2476","article-title":"GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation","volume":"9","author":"Ho","year":"2009","journal-title":"Nat Rev Immunol."},{"key":"2022092915292658800_B8","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1038\/srep29427","article-title":"Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL","volume":"6","author":"Dawidowska","year":"2016","journal-title":"Sci Rep."},{"issue":"11","key":"2022092915292658800_B9","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol."},{"issue":"1","key":"2022092915292658800_B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity."},{"issue":"26","key":"2022092915292658800_B11","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med."},{"issue":"11","key":"2022092915292658800_B12","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.4049\/jimmunol.1600130","article-title":"Heterologous vaccination and checkpoint blockade synergize to induce antileukemia immunity","volume":"196","author":"Manlove","year":"2016","journal-title":"J Immunol."},{"issue":"1","key":"2022092915292658800_B13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/imr.12768","article-title":"Cellular therapy: immune-related complications","volume":"290","author":"Oved","year":"2019","journal-title":"Immunol Rev."},{"issue":"2","key":"2022092915292658800_B14","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrclinonc.2017.176","article-title":"Acute lymphoblastic leukaemia in 2017: immunotherapy for ALL takes the world by storm","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"2022092915292658800_B15","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/1744666X.2021.1828067","article-title":"Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia","volume":"16","author":"Myers","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"issue":"9","key":"2022092915292658800_B16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/onci.22524","article-title":"How do CARs work?: Early insights from recent clinical studies targeting CD19","volume":"1","author":"Davila","year":"2012","journal-title":"OncoImmunology."},{"issue":"12","key":"2022092915292658800_B17","doi-asserted-by":"crossref","first-page":"a028472","DOI":"10.1101\/cshperspect.a028472","article-title":"Cytokines in cancer immunotherapy","volume":"10","author":"Waldmann","year":"2018","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"5","key":"2022092915292658800_B18","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nm.1953","article-title":"Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies","volume":"15","author":"Pellegrini","year":"2009","journal-title":"Nat Med."},{"issue":"5681","key":"2022092915292658800_B19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.1100369","article-title":"Cancer immunotherapy: a treatment for the masses","volume":"305","author":"Blattman","year":"2004","journal-title":"Science."},{"issue":"3","key":"2022092915292658800_B20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.4049\/jimmunol.155.3.1393","article-title":"Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts","volume":"155","author":"Zitvogel","year":"1995","journal-title":"J Immunol."},{"issue":"9668","key":"2022092915292658800_B21","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet."},{"issue":"6832","key":"2022092915292658800_B22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature."},{"issue":"6421","key":"2022092915292658800_B23","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1126\/science.aas9090","article-title":"NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination","volume":"362","author":"Ruscetti","year":"2018","journal-title":"Science."},{"issue":"8","key":"2022092915292658800_B24","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.4049\/jimmunol.1501291","article-title":"Adaptive immunity to leukemia is inhibited by cross-reactive induced regulatory T cells","volume":"195","author":"Manlove","year":"2015","journal-title":"J Immunol."},{"issue":"5","key":"2022092915292658800_B25","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2016-07-731091","article-title":"BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors","volume":"129","author":"Comoli","year":"2017","journal-title":"Blood."},{"issue":"10","key":"2022092915292658800_B26","first-page":"1315","article-title":"Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects","volume":"90","author":"Butt","year":"2005","journal-title":"Haematologica."},{"issue":"11","key":"2022092915292658800_B27","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment","volume":"111","author":"Chen","year":"2008","journal-title":"Blood."},{"issue":"5","key":"2022092915292658800_B28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0092-8674(00)80452-3","article-title":"Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF","volume":"91","author":"Kamijo","year":"1997","journal-title":"Cell."},{"issue":"13","key":"2022092915292658800_B29","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1182\/blood-2010-08-301267","article-title":"Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"117","author":"Boulos","year":"2011","journal-title":"Blood."},{"issue":"22","key":"2022092915292658800_B30","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2017-11-815506","article-title":"Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy","volume":"131","author":"Nishii","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2022092915292658800_B31","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1038\/leu.2009.69","article-title":"The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL","volume":"23","author":"Mian","year":"2009","journal-title":"Leukemia."},{"issue":"1","key":"2022092915292658800_B32","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.immuni.2015.12.006","article-title":"Compendium of immune signatures identifies conserved and species-specific biology in response to inflammation","volume":"44","author":"Godec","year":"2016","journal-title":"Immunity."},{"issue":"5","key":"2022092915292658800_B33","doi-asserted-by":"crossref","first-page":"e2144","DOI":"10.1371\/journal.pone.0002144","article-title":"Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs","volume":"3","author":"French","year":"2008","journal-title":"PLoS One."},{"issue":"26","key":"2022092915292658800_B34","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N Engl J Med."},{"issue":"1","key":"2022092915292658800_B35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.32614\/RJ-2016-021","article-title":"mclust 5: clustering, classification and density estimation using Gaussian finite mixture models","volume":"8","author":"Scrucca","year":"2016","journal-title":"R J."},{"issue":"7","key":"2022092915292658800_B36","doi-asserted-by":"crossref","first-page":"e41658","DOI":"10.1371\/journal.pone.0041658","article-title":"Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One."},{"issue":"12","key":"2022092915292658800_B37","doi-asserted-by":"crossref","first-page":"e83069","DOI":"10.1371\/journal.pone.0083069","article-title":"A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One."},{"issue":"12","key":"2022092915292658800_B38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41408-017-0019-6","article-title":"The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents","volume":"7","author":"Romano","year":"2017","journal-title":"Blood Cancer J."},{"issue":"6","key":"2022092915292658800_B39","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1089\/thy.2018.0684","article-title":"Low lymphocyte-to-monocyte ratios are associated with poor overall survival in anaplastic thyroid carcinoma patients","volume":"29","author":"Ahn","year":"2019","journal-title":"Thyroid."},{"issue":"6","key":"2022092915292658800_B40","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ccell.2020.04.015","article-title":"Extensive remodeling of the immune microenvironment in B cell acute lymphoblastic leukemia","volume":"37","author":"Witkowski","year":"2020","journal-title":"Cancer Cell."},{"issue":"19-20","key":"2022092915292658800_B41","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev."},{"issue":"10","key":"2022092915292658800_B42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri.2016.80","article-title":"Regulatory circuits of T cell function in cancer","volume":"16","author":"Speiser","year":"2016","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"2022092915292658800_B43","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"2022092915292658800_B44","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood."},{"issue":"4","key":"2022092915292658800_B45","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell."},{"issue":"5","key":"2022092915292658800_B46","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"2009","journal-title":"Cancer Cell."},{"issue":"12","key":"2022092915292658800_B47","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol."},{"issue":"6","key":"2022092915292658800_B48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2022092915292658800_B49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood."},{"issue":"1","key":"2022092915292658800_B50","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/asheducation-2017.1.102","article-title":"Treatment-free remission in CML: who, how, and why?","volume":"2017","author":"Mahon","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"498","key":"2022092915292658800_B51","doi-asserted-by":"crossref","first-page":"eaat8549","DOI":"10.1126\/scitranslmed.aat8549","article-title":"Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses","volume":"11","author":"Zamora","year":"2019","journal-title":"Sci Transl Med."},{"issue":"12","key":"2022092915292658800_B52","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/sj.leu.2404924","article-title":"Deregulation of the Wilms\u2019 tumour gene 1 protein (WT1) by BCR\/ABL1 mediates resistance to imatinib in human leukaemia cells","volume":"21","author":"Svensson","year":"2007","journal-title":"Leukemia."},{"issue":"4","key":"2022092915292658800_B53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/imm.12472","article-title":"Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation","volume":"145","author":"Schmied","year":"2015","journal-title":"Immunology."},{"issue":"2","key":"2022092915292658800_B54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.leu.2404047","article-title":"Wilms\u2019 tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring","volume":"20","author":"Boublikova","year":"2006","journal-title":"Leukemia."},{"issue":"3","key":"2022092915292658800_B55","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood."},{"issue":"3","key":"2022092915292658800_B56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat Can."},{"issue":"7","key":"2022092915292658800_B57","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood."},{"issue":"5238","key":"2022092915292658800_B58","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1126\/science.270.5238.908.a","article-title":"IL-12 deaths: explanation and a puzzle","volume":"270","author":"Cohen","year":"1995","journal-title":"Science."},{"issue":"4","key":"2022092915292658800_B59","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci China Life Sci."},{"issue":"18","key":"2022092915292658800_B60","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood."},{"key":"2022092915292658800_B61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2017.12.003","article-title":"CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity","volume":"8","author":"Kueberuwa","year":"2017","journal-title":"Mol Ther Oncolytics."},{"issue":"2","key":"2022092915292658800_B62","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/leu.2014.215","article-title":"IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia","volume":"29","author":"Pegram","year":"2015","journal-title":"Leukemia."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/13\/1507\/1922860\/bloodbld2021014495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/140\/13\/1507\/1922860\/bloodbld2021014495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T19:10:23Z","timestamp":1675797023000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/140\/13\/1507\/485490\/Impact-of-T-cell-immunity-on-chemotherapy-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":62,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,9,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021014495","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]}}}